Status and phase
Conditions
Treatments
About
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Full description
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Renal Cell Carcinoma Inclusion Criteria
Renal Cell Carcinoma Exclusion Criteria
Metastatic Castration-Resistant Prostate Cancer Inclusion Criteria
Documentation of disease: progressive CRPC with histologically or cytologically confirmed adenocarcinoma of the prostate.
Patients must have radiologically evident metastatic disease, but it can be measurable or non-measurable disease:
1-3 prior lines of therapy, including at least one newer generation androgen synthesis inhibitor (e.g., abiraterone) or androgen receptor antagonist (e.g., enzalutamide, apalutamide, darolutamide).
Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
Metastatic Castration-Resistant Prostate Cancer Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
502 participants in 5 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal